Forward-Looking Safe-Harbor Statement

This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on our current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on our business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in our periodic and current reports filed with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K for the year ended December 31, 2020, once filed, and subsequent reports. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law.
PUMA’s Pharmacy and Distributor Network

**Hub Services**

** Patients **

** Sites of Care **

- Academic hospitals
- Community hospitals
- Physician Practices
- Others (VA, DOD)

** Specialty Pharmacy Network (SP) **

- Acaria health
- Accredo
- CVS
- ONCO 360
- Optum / Diplomat
- Biologics

** Specialty Distributor Network (SD) **

- McKesson
- ASD/Oncology supply
- Cardinal health
~$50 Million Net NERLYNX Revenue in Q4’20

Quarterly Net Revenue (in $MM)

Q3’2017: 6.1
Q4’2017: 20.1
Q1’2018: 36.0
Q2’2018: 50.8
Q3’2018: 52.6
Q4’2018: 61.1
Q1’2019: 45.6
Q2’2019: 53.8
Q3’2019: 53.5
Q4’2019: 58.7
Q1’2020: 48.6
Q2’2020: 48.8
Q3’2020: 49.3
Q4’2020: 50.0
3,600 Ex-factory Bottles were Sold in Q4’20

Bottles Sold (SP + SD) by Quarter

Includes Commercial SP and SD
~38% of Patients in Q4’20 Started at a Reduced Dose

% of patients starting at reduced dose

Reduced dose defined as fewer than 6 pills per day
# Rest of World Partnerships – Timelines

<table>
<thead>
<tr>
<th>Region</th>
<th>Partner</th>
<th>Regulatory / Launch Milestones</th>
</tr>
</thead>
</table>
| Australia / SE Asia     | Specialised Therapeutics | • March 2019 – Approved in Australia  
• December 2019 – Approved in Singapore  
• Q2/Q3 2020 – Approved in Brunei, Malaysia, New Zealand |
| Israel                  | McGDSD    | • Q1 2020 – Launched  
• Q3 2020 – Approved in metastatic breast cancer |
| Canada                  | Knight    | • July 2019 – Approved  
• September 2020 – metastatic sNDS accepted by HC |
| Latin America           | PINT PHARMA | • Q1 2020 – Argentina Launched; mBC approved January 2021  
• Q2 2020 – Approved in Chile  
• Q3 2020 – Approved in Ecuador  
• 2021 – Expected approvals in Brazil, Colombia, Mexico, Peru |
| Europe                  | Pierre Fabre | • Q4 2019 – Germany, UK, Austria Launched  
• Q1 2020 – Sweden Launched  
• Q2 2020 – Hong Kong Launched  
• Q2 2020 – Approved in China  
• Q3 2020 – Approved in Taiwan  
• Q4 2020 – Finland / Switzerland Launched |
| South Korea             | BIXINK    | • October 2020 – NDA Filed |